Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results Life Science Investing
Seegnal Expands Deployment of Seegnal's Prescription Intelligence Platform at Tel Aviv Sourasky Medical Center, a Leading Israeli Public Medical Center and Global Referral Center Biotech Investing
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT12396, a Mutant-selective JAK2V617F Inhibitor Life Science Investing
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team Life Science Investing
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team Life Science Investing
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 Life Science Investing
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer Life Science Investing
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit Life Science Investing
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union Life Science Investing
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 Life Science Investing
